A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas

被引：47

作者：

Feugier, Pierre ^{[1
,2
]}

机构：

[1] Ctr Hosp Univ Nancy, Serv Hematol, F-54511 Vandoeuvre Les Nancy, France

[2] Univ Lorraine, INSERM 954, Unite NGERE, F-54000 Nancy, France

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 09期

关键词：

CD20; monoclonal antibody; non-Hodgkin's lymphoma; STEM-CELL TRANSPLANTATION; DETUDE-DES-LYMPHOMES; HIGH-DOSE CHEMOTHERAPY; PROSPECTIVE RANDOMIZED-TRIAL; PROGRESSION-FREE SURVIVAL; RELAPSED FOLLICULAR LYMPHOMA; BENDAMUSTINE PLUS RITUXIMAB; 3-WEEKLY CHOP CHEMOTHERAPY; EVENT-FREE SURVIVAL; HIGH TUMOR BURDEN;

D O I：

10.2217/fon.15.57

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Rituximab is a type I anti-CD20 monoclonal antibody, which stabilizes CD20 on lipid rafts, promoting antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. It is the first targeted therapy used in B-cell malignancies and has revolutionized their treatment, without excess of toxicity. In combination with chemotherapy, it has significantly improved response rates and progression-free survival and, for some of them, overall survival of patients with diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma. Moreover, it has been shown to improve progression-free survival in maintenance in follicular lymphoma as well as mantle cell lymphoma. Improvement of its efficacy includes exploration of resistance mechanisms, pharmacokinetics parameters, role of vitamin D and evaluation of subcutaneous route, among others.

引用

页码：1327 / 1342

页数：16

共 104 条

[1] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study [J].

Ansell, Stephen M. ;

Tang, Hui ;

Kurtin, Paul J. ;

Koenig, Patricia A. ;

Inwards, David J. ;

Shah, Keith ;

Ziesmer, Steven C. ;

Feldman, Andrew L. ;

Rao, Radha ;

Gupta, Mamta ;

Erlichman, Charles ;

Witzig, Thomas E. .

LANCET ONCOLOGY, 2011, 12 (04) :361-368

[2] Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial [J].

Ardeshna, Kirit M. ;

Qian, Wendi ;

Smith, Paul ;

Braganca, Nivette ;

Lowry, Lisa ;

Patrick, Pip ;

Warden, June ;

Stevens, Lindsey ;

Pocock, Christopher F. E. ;

Miall, Fiona ;

Cunningham, David ;

Davies, John ;

Jack, Andrew ;

Stephens, Richard ;

Walewski, Jan ;

Ferhanoglu, Burhan ;

Bradstock, Ken ;

Linch, David C. .

LANCET ONCOLOGY, 2014, 15 (04) :424-435

[3] Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial [J].

Ardeshna, KM ;

Smith, P ;

Norton, A ;

Hancock, BW ;

Hoskin, PJ ;

MacLennan, KA ;

Marcus, RE ;

Jelliffe, A ;

Hudson, GV ;

Linch, DC .

LANCET, 2003, 362 (9383) :516-522

[4] Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis [J].

Barnes, J. A. ;

LaCasce, A. S. ;

Feng, Y. ;

Toomey, C. E. ;

Neuberg, D. ;

Michaelson, J. S. ;

Hochberg, E. P. ;

Abramson, J. S. .

ANNALS OF ONCOLOGY, 2011, 22 (08) :1859-1864

[5] Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens [J].

Bedognetti, Davide ;

Zoppoli, Gabriele ;

Massucco, Carlotta ;

Zanardi, Elisa ;

Zupo, Simonetta ;

Bruzzone, Andrea ;

Sertoli, Mario Roberto ;

Balleari, Enrico ;

Racchi, Omar ;

Messina, Marco ;

Caltabiano, Graziano ;

Icardi, Giancarlo ;

Durando, Paolo ;

Marincola, Francesco M. ;

Boccardo, Francesco ;

Ferrarini, Manlio ;

Ansaldi, Filippo ;

De Maria, Andrea .

JOURNAL OF IMMUNOLOGY, 2011, 186 (10) :6044-6055

[6] Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients [J].

Benekli, M ;

Hahn, T ;

Shafi, F ;

Qureshi, A ;

Alam, AR ;

Czuczman, MS ;

Bernstein, ZP ;

Chanan-Khan, AA ;

Becker, JL ;

McCarthy, PL .

BONE MARROW TRANSPLANTATION, 2003, 32 (02) :139-143

[7] Vitamin D Deficiency Impairs Rituximab-Mediated Cellular Cytotoxicity and Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With but Not Without Rituximab [J].

Bittenbring, Joerg Thomas ;

Neumann, Frank ;

Altmann, Bettina ;

Achenbach, Marina ;

Reichrath, Joerg ;

Ziepert, Marita ;

Geisel, Juergen ;

Regitz, Evi ;

Held, Gerhard ;

Pfreundschuh, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (29) :3242-+

[8] CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients:: A study by the Groupe d'Etude des Lymphomes de I'Adulte [J].

Bonnet, Christophe ;

Fillet, Georges ;

Mounier, Nicolas ;

Ganem, Gard ;

Molina, Thierry Jo ;

Thieblemont, Catherine ;

Ferme, Christophe ;

Quesnel, Bruno ;

Martin, Claude ;

Gisselbrecht, Christian ;

Tilly, Herve ;

Reyes, Felix .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :787-792

[9]

Boross P, 2012, AM J CANCER RES, V2, P676

[10] Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe D'Etude des Lymphomes Folliculaires [J].

Brice, P ;

Bastion, Y ;

Lepage, E ;

Brousse, N ;

Haioun, C ;

Moreau, P ;

Straetmans, N ;

Tilly, H ;

Tabah, I ;

SolalCeligny, P .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1110-1117

← 1 2 3 4 5 6 7 8 9 10 →